Welcome to BioSeeker Group!

Drug Target Atlas in Oncology

Additional Information

Published Date Aug 9, 2016
PDF Fact Sheet View Fact Sheet for the report Drug Target Atlas in Oncology in PDF
Format One Year of Online Access
Publisher BioSeeker Group

Availability: In stock

$7,950.00

Quick Overview

System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Drug Target Atlas in Oncology.

    To find out more about Drug Target Atlas in Oncology, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Drug Target Atlas in Oncology is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or
Extra value: One year of free online updates included with this product

"Drug Target Atlas in Oncology" helps you to understand the complex world of commercial development in by identifying the most promising Target Approaches in development today from your competitors and prospective partners and revealing the areas where your company can succeed.

"Drug Target Atlas in Oncology" is a one-of-a-kind, authoritative target analyzer tool, integrated with drug pipeline information covering commercial developments of molecular drug targets in from 1579 companies plus partners. With the "Drug Target Atlas in Oncology" at your fingertips, you are able to identify opportunities and avoid pitfalls in the area of .

The Target Atlas provides unparalleled, in-depth R&D analysis for each of the 48 approved drug targets and 1253 targets in development in whether they are established or novel, first-in-class drug targets. You can analyze these as both Single Targets as well as Target Clusters, which is a great feature when you are dealing with many targets at the same time.

Furthermore, this target analyzer comes integrated with full drug pipeline information for 5763 drugs which lets you effortlessly access relevant, in-depth information about each drug linked to a specific target.

The Target Atlas gives you the information you need to make successful decisions and understand fully what is happening in the field of from a target and drug development perspective. This is information you can’t get anywhere else and in addition, you will stay up to date as your Target Atlas comes powered with 1 year of free online updates!

Drug Target Atlas in Oncology is a Great Product for:

Target Scouting

First-in-class analysis

R&D profiling

Understanding Target Approaches

Target-Target Interaction Analysis

Mapping the competition

Who is already using the Target Atlas series to aid their day to day work?

CEO and CSO’s

Clinical and preclinical development specialists

Business development and licensing specialists

Search and Evaluation departments

Corporate strategy, product and portfolio analysts

Venture capital and Investment Specialists

Gain Insights into Targets

The majority (97%) of drug targets pursued for the treatment of are proteins, however there are also nucleic acid and polysaccharide target(s) represented in the "Drug Target Atlas in Oncology". The 1264 separate human protein targets among drugs represent 104 different types of molecular functions and are directly related to the mechanism of action for these drugs.

Get the full picture of the target landscape of so that you are basing your decisions on all the available information, independently acquired for you by our expert team of analysts.

Using the Target Atlas allows you to not only save time, but also leads to you conducting better assessments which you can back up with real data. A built-in infographics module makes it easy to export graphs and charts to include in your own reports and presentations to other stakeholders.

Additional Key Facts of Targets in Include

Number of Targets
Targets with mutations1013
Targets with tumor expression profiles1029
Targets which are strongly implicated with certain types of cancer107
Targets with biological structures638

In the Target Atlas you will get independently sourced information in a context found nowhere else, benefiting your research, analyses and decisions.

Perform Target Cluster Analysis

You can simultaneously access any number of the total 1301 targets covered in this product by using up to 24 different pipeline parameters, including: Target, Company, Stage of Development, Compound Type, Indications, Pathway, Mutation, Subcellular Location, etc.

On any Target Query the Target Cluster Analysis will deliver

Target Summary - Outlining the number and identity of Targets, Target Approaches, Drugs, Indications and Companies in both Tables and Charts.

Target - All targets sortable by number of Drugs, Indications, Companies and Highest Stage of Development. Access to graphical breakdowns of targets by Stage, Compound Type, Indication and Company.

Target Approach* - All Target Approaches sortable by number of Drugs, Indications, Companies and Highest Stage of Development. Access to graphical breakdowns of Target Approaches by Stage, Compound Type, Indication and Company.

Competitive Review - First-in-Class analysis of all Target Approaches by stage of development or independent of stage. Based upon the 24 filter settings available, identify the number and identity of unique Target Approaches in cancer in any context.

* A Target Approach visualizes each drug according to its complete range of targets, hence providing a superior sharpness in target comparison among drugs. Each Target Approach represents a distinct way of attacking cancer.

Generate 1301 Target Analysis Reports, tailored to your specific interest.

You can generate a target report on any of the 1301 included targets in "Drug Target Atlas in Oncology". Furthermore, you can tailor any of these reports based on Companies, Type of Compounds, Indications, Stage of Development, etc.

Each Target Analysis Report Includes:

Gene/Protein Overview

Mutational Review

Pathway Matching

Tumor Expression Profiles

Target-Target Analysis

Target Approach Analysis

R&D Progression Analysis, covering Compounds, Drugs and Companies


Access to Pipeline Information on 5763 Drugs

The Target Atlas comes integrated with in-depth drug pipeline information. With a simple click you can effortlessly access relevant information about each drug included in any target report. A drug profile includes:

Drug Name & Synonyms

Principal Company

Partners and Partner Status

Drug Description

Fillings and Approvals

Sales Figures

Deals and Licensing

Compound Data

Patent Data

Target and Molecular Function of Target

Target Localization

Mutational Profiling

Biological Structures

Target Expression Profiles

Targeted Pathways

Mechanism of Action

Developmental Projects

Developmental information (Discovery-Phase IV)


**Information included in a drug profile is dependent on the drug’s maturity and other factors.

Cut Your Opportunity Costs Today


Would your work benefit from having a full understanding of the development within from a Target/Drug point of view? When you consider the substantial value and effort involved in the projects you are working on, does it make sense to have a third-party analysis tool to validate and help guide your decision making with confidence?

If yes, then purchasing the "Drug Target Atlas in Oncology" represents a unique opportunity to get these in-depth insights today. With one year of free online updates and fully exportable data and charts, you will have access to the latest information and can easily present your findings to your colleagues and stakeholders.

Welcome to having the world of at your fingertips with "Drug Target Atlas in Oncology"!

System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Drug Target Atlas in Oncology.
    To find out more about Drug Target Atlas in Oncology, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Drug Target Atlas in Oncology is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Drugs' category:


Notch Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 335 companies plus partners who are today developing 416 Notch pathway targeting drugs in 1497 developmental projects in cancer across 232 different targets. In addition, there are 4 suspended drugs and another 236 drugs where development has been ceased. Learn More


Target Atlas in Biliary Cancer: A Competitive Outlook
System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)
Learn More

Other selected research from the 'Drug Pipeline Updates' category:


ErbB Signaling Pathway in Cancer Drug Pipeline Update
BioSeeker Group have identified 366 companies plus partners who are today developing 528 ErbB signaling pathway targeting drugs in 1896 developmental projects in cancer across 187 different targets. In addition, there is 1 suspended drug and another 202 drugs where development has been ceased. Learn More


Lung Cancer Drug Pipeline Update
BioSeeker Group have identified 552 companies plus partners who are today developing 809 lung cancer drugs in 884 developmental projects in cancer across 431 different targets. In addition, there are 10 suspended drugs and another 267 drugs where development has been ceased. Learn More

Other selected research from the 'R&D' category:


Fierce 15 in Oncology Drug Pipeline Update
BioSeeker Group have identified 72 companies plus partners who are today developing 201 Fierce 15 drugs in 600 developmental projects in cancer across 130 different targets. In addition, there are 2 suspended drugs and another 34 drugs where development has been ceased. Learn More


Target Atlas in Melanoma: A Competitive Outlook
System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)
Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Lung Cancer, Cancer Vaccines and Peptides
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lung Cancer), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Peptides). Learn More


Radiation Therapy in Oncology Drug Pipeline Update
BioSeeker Group have identified 322 companies plus partners who are today developing 313 radiation therapy drugs in 692 developmental projects in cancer across 179 different targets. In addition, there are 7 suspended drugs and another 150 drugs where development has been ceased. Learn More